Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambroxol SCHEMBL28472066 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL423712 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL18702 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL29380194 | 1.00 | CYP2D6 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL99455 | 0.99 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL6601413 | 0.99 | CYP3A4 (1.00) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL1648757 | 0.97 | CYP2D6 (0.94) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| Ambroxol SCHEMBL11533052 | 0.93 | CYP2D6 (0.87) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL24446418 | 0.92 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 | |
| SCHEMBL22927201 | 0.92 | CYP2D6 (0.84) | CYP2D6SLC6A4KCNH2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346671-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | NEUERE, LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11730690-B2 | Use of ambroxol to improve skin barrier function | NEUERE, LLC (US) | 2023-08-22 | — | — | US | disclosed |
| US-11583543-B2 | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | NEUERE, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022090845-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE CRYSTALLINE AMBROXOL HYDROCHLORIDE | SHIVALIK RASAYAN LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| EP-2793872-B1 | COMBINATION OF A COMPOUND HAVING THE ABILITY TO REARRANGE A LYSOSOMAL ENZYME AND AMBROXOL AND/OR A DERIVATIVE OF AMBROXOL | CENTOGENE IP GMBH (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-20200215089-A1 | AMBROXOL TO IMPROVE AND/OR EXTEND HEALTHSPAN, LIFESPAN AND/OR MENTAL ACUITY | NEUERE, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200060955-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | NEUERE, LLC (US) | 2020-02-27 | — | — | US | disclosed |
| US-20190254992-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED (IL) | 2019-08-22 | — | — | US | disclosed |
| US-20150190377-A1 | NEURONAL REGENERATION | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-07-09 | — | — | US | disclosed |
| US-20150190377-A1 | NEURONAL REGENERATION | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-07-09 | — | — | US | disclosed |
| US-7378412-B2 | Pharmaceutical compounds | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1169294-B1 | PHARMACEUTICAL COMPOUNDS | NICOX SA (FR) | 2007-12-05 | — | — | EP | disclosed |
| US-20070212339-A1 | Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung Diseases | ESPARMA GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070197499-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-08-23 | — | — | US | disclosed |
| US-20070197499-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-08-23 | — | — | US | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7186753-B1 | Pharmaceutical compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-20040219207-A1 | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2004-11-04 | — | — | US | disclosed |
| US-20040219207-A1 | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197499-A1 | Pharmaceutical compounds | NR0B2, NR0B1, CYP11B2 | CYP2D6 63/4885SLC6A4 936/4885KCNH2 2096/4885 |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | CYP2D6 453/4885SLC6A4 823/4885KCNH2 3716/4885 |
| US-20190254992-A1 | COMBINATIONS OF BETA-GLYCOLIPIDES AND 4-[(2-AMINO-3,5-DIBROMOPHENYL)METHYLAMINO]CYCLOHEXAN-1-OL, COMPOSITIONS AND USES THEREOF IN THE TREATMENT OF DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING AND PROTEIN AGGREGATIONS | SSB, PMP22, TTR | CYP2D6 4760/4885SLC6A4 4842/4885KCNH2 4669/4885 |
| US-20040219207-A1 | Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases | ACE, LCT, CTSA | CYP2D6 2025/4885SLC6A4 3525/4885KCNH2 4446/4885 |
| US-20230346671-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | CUTA, MCOLN3, MMP1 | CYP2D6 1737/4885SLC6A4 2620/4885KCNH2 986/4885 |
| US-20070212339-A1 | Use Of At Least One Effector Of Glutathione Metabolism Together With Alpha-Lipoic Acid For The Treatment Of Chronically Obstructive Lung Diseases | GGT1, GPX1, GSTA1 | CYP2D6 1993/4885SLC6A4 3205/4885KCNH2 4720/4885 |
| US-20200215089-A1 | AMBROXOL TO IMPROVE AND/OR EXTEND HEALTHSPAN, LIFESPAN AND/OR MENTAL ACUITY | BTD, BRD3, GLA | CYP2D6 4244/4885SLC6A4 1184/4885KCNH2 1919/4885 |
| US-11583543-B2 | Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity | BTD, BRD3, GLA | CYP2D6 4244/4885SLC6A4 1184/4885KCNH2 1919/4885 |
| US-20200060955-A1 | USE OF AMBROXOL TO IMPROVE SKIN BARRIER FUNCTION | CUTA, MCOLN3, MCOLN2 | CYP2D6 1492/4885SLC6A4 2732/4885KCNH2 830/4885 |
| US-20150190377-A1 | NEURONAL REGENERATION | GAP43, DCX, BDNF | CYP2D6 4876/4885SLC6A4 1895/4885KCNH2 3736/4885 |
| US-11730690-B2 | Use of ambroxol to improve skin barrier function | CUTA, MCOLN3, MCOLN2 | CYP2D6 1492/4885SLC6A4 2732/4885KCNH2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.